Japan's Solasia begins Phase II trial of lymphoma drug darinaparsin

Japan-based Solasia Pharma has started an Asian Multinational Phase II trial of SP-02 (darinaparsin) for injection (SP-02L) to treat relapsed and refractory peripheral T-cell lymphoma (PTCL).
Source: Drug Development Technology - Category: Pharmaceuticals Source Type: news